Regen BioPharma Files Utility Patent Application for Immuno-Oncology Therapeutic dCellVax

Regen BioPharma Files Utility Patent Application for Immuno-Oncology Therapeutic dCellVax
Publicly traded biotechnology company, Regen Biopharma, Inc. has just announced it has filed a utility patent application with the US Patent and Trademark Office for its breakthrough immuno-oncology treatment, dCellVax. This therapeutic works by stimulating the body’s dendritic cells to help activite immune responses against cancer. Regen’s application is based on the company’s experience in harnessing dendritic cells,

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Tagged , .

Anna is responsible for the scripting and production of video news content. Her skills as a registered nurse as well as a proven video content creator on YouTube and other social media platforms allow her to create video news reports that are engaging and easy to understand for patients.

Leave a Comment

Your email address will not be published. Required fields are marked *